pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search

calendar

8,100 catalysts · 5,811 phase readout · 2,283 8k filing · 416 earnings · 3 pdufa · 2 approval · 1 adcom

★ save view↓export CSV
next 91 dayslessmore
MonWedFri
2026-08-10: 14 catalysts2026-08-11: 16 catalysts2026-08-12: 19 catalysts2026-08-13: 19 catalysts2026-08-14: 4 catalysts2026-08-15: 0 catalysts2026-08-16: 0 catalysts2026-08-17: 1 catalyst2026-08-18: 2 catalysts2026-08-19: 2 catalysts2026-08-20: 0 catalysts2026-08-21: 0 catalysts2026-08-22: 0 catalysts2026-08-23: 0 catalysts2026-08-24: 0 catalysts2026-08-25: 0 catalysts2026-08-26: 1 catalyst2026-08-27: 1 catalyst2026-08-28: 0 catalysts2026-08-29: 0 catalysts2026-08-30: 0 catalysts2026-08-31: 0 catalysts2026-09-01: 1 catalyst2026-09-02: 0 catalysts2026-09-03: 1 catalyst2026-09-04: 0 catalysts2026-09-05: 0 catalysts2026-09-06: 0 catalysts2026-09-07: 0 catalysts2026-09-08: 0 catalysts2026-09-09: 0 catalysts2026-09-10: 0 catalysts2026-09-11: 0 catalysts2026-09-12: 0 catalysts2026-09-13: 0 catalysts2026-09-14: 0 catalysts2026-09-15: 0 catalysts2026-09-16: 0 catalysts2026-09-17: 0 catalysts2026-09-18: 0 catalysts2026-09-19: 0 catalysts2026-09-20: 0 catalysts2026-09-21: 0 catalysts2026-09-22: 0 catalysts2026-09-23: 2 catalysts2026-09-24: 0 catalysts2026-09-25: 0 catalysts2026-09-26: 0 catalysts2026-09-27: 0 catalysts2026-09-28: 0 catalysts2026-09-29: 0 catalysts2026-09-30: 0 catalysts2026-10-01: 0 catalysts2026-10-02: 0 catalysts2026-10-03: 0 catalysts2026-10-04: 0 catalysts2026-10-05: 0 catalysts2026-10-06: 0 catalysts2026-10-07: 0 catalysts2026-10-08: 2 catalysts2026-10-09: 0 catalysts2026-10-10: 0 catalysts2026-10-11: 0 catalysts2026-10-12: 0 catalysts2026-10-13: 1 catalyst2026-10-14: 1 catalyst2026-10-15: 0 catalysts2026-10-16: 0 catalysts2026-10-17: 0 catalysts2026-10-18: 0 catalysts2026-10-19: 1 catalyst2026-10-20: 2 catalysts2026-10-21: 2 catalysts2026-10-22: 2 catalysts2026-10-23: 1 catalyst2026-10-24: 0 catalysts2026-10-25: 0 catalysts2026-10-26: 1 catalyst2026-10-27: 8 catalysts2026-10-28: 11 catalysts2026-10-29: 20 catalysts2026-10-30: 4 catalysts2026-10-31: 0 catalysts2026-11-01: 0 catalysts2026-11-02: 8 catalysts2026-11-03: 14 catalysts2026-11-04: 21 catalysts2026-11-05: 36 catalysts2026-11-06: 2 catalysts2026-11-07: 0 catalysts2026-11-08: 0 catalysts
view
agendamonth
show past →
sort
soonestlatesttypesponsoralpha
type
  • phase readout5,811
  • 8k filing2,283
  • earnings416
  • pdufa3
  • approval2
  • adcom1
therapy area

no tagged catalysts yet

Week of Aug 3, 2026

35
›Aug 6, 20268k filing4d ago$APUS — Apimeds Pharmaceuticals US, Inc. (APUS) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 6, 20268k filing4d ago$TNGX — Tango Therapeutics, Inc. (TNGX) — 8-K filing

Items: 5.02

full page →edgar 8k ↗
›08/07/2026adcom3d agoAdvisory Committee Calendar

This page contains notices of advisory committee meetings. Refer to the individual meeting link below for more information on the anticipated format of each meeting. For previous years' advisory committee calendars, see the FDA Archive.

full page →fda adcom ↗
›Aug 7, 20268k filing3d ago$REPL — Replimune Group, Inc. (REPL) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$VSTM — Verastem, Inc. (VSTM) — 8-K filing

Items: 1.01, 2.03, 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$EMBC — Embecta Corp. (EMBC) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$TMCI — TREACE MEDICAL CONCEPTS, INC. (TMCI) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$NRXP — NRX Pharmaceuticals, Inc. (NRXP) — 8-K filing

Items: 7.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d agoKIORA PHARMACEUTICALS INC (KPRX, KPHMW) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$NERV — Minerva Neurosciences, Inc. (NERV) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$TNGX — Tango Therapeutics, Inc. (TNGX) — 8-K filing

Items: 5.02, 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ANIP — ANI PHARMACEUTICALS INC (ANIP) — 8-K filing

Items: 2.02, 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ETST — Earth Science Tech, Inc. (ETST) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$GYRE — GYRE THERAPEUTICS, INC. (GYRE) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$XBIO — Xenetic Biosciences, Inc. (XBIO) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d agobioAffinity Technologies, Inc. (BIAF, BIAFW) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ATOS — ATOSSA THERAPEUTICS, INC. (ATOS) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$APYX — Apyx Medical Corp (APYX) — 8-K filing

Items: 5.02, 5.07, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ATYR — aTYR PHARMA INC (ATYR) — 8-K filing

Items: 2.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d agoBioKey (Cayman), Inc. — 8-K filing

Items: 4.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d agoOSR Health, Inc. (OSRH, OSRHW) — 8-K filing

Items: 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ENTX — Entera Bio Ltd. (ENTX) — 8-K filing

Items: 2.02, 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$BHVN — Biohaven Ltd. (BHVN) — 8-K filing

Items: 5.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$BRVE — Braveheart Bio, Inc. (BRVE) — 8-K filing

Items: 5.03, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$XTNT — Xtant Medical Holdings, Inc. (XTNT) — 8-K filing

Items: 5.07, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$CRMD — CorMedix Inc. (CRMD) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$BSEM — BioStem Technologies, Inc. (BSEM) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ELUT — ELUTIA INC. (ELUT) — 8-K filing

Items: 3.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$CTSO — Cytosorbents Corp (CTSO) — 8-K filing

Items: 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ABCL — AbCellera Biologics Inc. (ABCL) — 8-K filing

Items: 8.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$MBOT — Microbot Medical Inc. (MBOT) — 8-K filing

Items: 1.01, 5.02, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$TFX — TELEFLEX INC (TFX) — 8-K filing

Items: 8.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$CELU — Celularity Inc (CELU) — 8-K filing

Items: 5.02

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$ISPC — iSpecimen Inc. (ISPC) — 8-K filing

Items: 1.01, 7.01, 9.01

full page →edgar 8k ↗
›Aug 7, 20268k filing3d ago$COYA — Coya Therapeutics, Inc. (COYA) — 8-K filing

Items: 5.02

full page →edgar 8k ↗

Week of Jan 4, 2027

1
›Jan 4, 2027pdufa147dPDUFA — 2027-01-04

action date of January 4, 2027

full page →pdufa extract ↗

Week of Jan 18, 2027

1
›Jan 21, 2027pdufa164dPDUFA — 2027-01-21Ultragenyx Pharmaceutical Inc.

action date of Jan. 21, 2027

full page →pdufa extract ↗

Date TBD

13
›TBDapprovalOZURDEX (DEXAMETHASONE) — FDA approvaldexamethasone LA

Sponsor: ABBVIE. Form: IMPLANT. Route: INTRAVITREAL

full page →dexamethasone LA →fda approvals ↗
›TBDapprovalTRILEPTAL (OXCARBAZEPINE) — FDA approvalOXCARBAZEPINE

Sponsor: NOVARTIS. Form: TABLET. Route: ORAL

full page →OXCARBAZEPINE →fda approvals ↗
›RECRUITINGphase readoutNCT06924671: GLA:D Back Canada - a Program for Chronic and Persistent Low Back Pain

Sponsor: University of Alberta. Phase: . Conditions: Low Back Pain

full page →ctgov ↗
›COMPLETEDphase readoutNCT07542236: Hip and Ankle Mobility Rehabilitation for Soccer Players With Patellofemoral Pain

Sponsor: Beijing Sport University. Phase: NA. Conditions: Patellofemoral Pain

full page →ctgov ↗
›ACTIVE_NOT_RECRUITINGphase readoutNCT06941844: A Phase 3 Trial of MM120 for Major Depressive Disorder (Emerge)Definium Therapeutics, Inc.

Sponsor: Definium Therapeutics US, Inc.. Phase: PHASE3. Conditions: Major Depressive Disorder

full page →ctgov ↗
›RECRUITINGphase readoutNCT06466434: Prebiotic Food-enriched Diet (PreFED) to Enhance the Microbiome and Response to First-line Immunotherapy in Unresectable Melanoma

Sponsor: M.D. Anderson Cancer Center. Phase: PHASE2. Conditions: Unresectable Melanoma

full page →ctgov ↗
›RECRUITINGphase readoutNCT06806709: Reducing Blood Culture Contamination With the Use of a Needle-less Blood Draw Device (The PIVO Trial)

Sponsor: The University of Queensland. Phase: NA. Conditions: Blood Culture Contamination, Infection

full page →ctgov ↗
›RECRUITINGphase readoutNCT07178509: A Study of SCAD Using Stress Contrast EchocardiographyMayo Clinic

Sponsor: Mayo Clinic. Phase: . Conditions: Spontaneous Coronary Artery Dissection

full page →ctgov ↗
›COMPLETEDphase readoutNCT07403409: Scapular Repeated Contractions Facilitation Versus Hold-relax Techniques in Patients With Adhesive Capsulitis

Sponsor: Riphah International University. Phase: NA. Conditions: Adhesive Capsulitis of the Shoulder

full page →ctgov ↗
›COMPLETEDphase readoutNCT06721663: Multisensory Environment Stimulation Therapy on Postural Control in Cerebral Palsy

Sponsor: October 6 University. Phase: NA. Conditions: Cerebral Palsy

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT06624787: Development Of A Rapid Diagnostic Test To Identify Crimean-Congo Haemorrhagic Fever At The Point-Of-Care

Sponsor: Liverpool School of Tropical Medicine. Phase: NA. Conditions: Crimean-Congo Haemorrhagic Fever

full page →ctgov ↗
›NOT_YET_RECRUITINGphase readoutNCT07527221: Safety and Tolerability of ZE74-0282 in Healthy VolunteersCerta Therapeutics Pty Ltd

Sponsor: Eilean Therapeutics AU Pty Ltd. Phase: PHASE1. Conditions: Healthy Volunteers

full page →ctgov ↗
›RECRUITINGphase readoutNCT07329114: Healing Electroceutical Dressing for the Recovery of Open Wounds (HERO)

Sponsor: Chandan Sen. Phase: NA. Conditions: Wound Heal, Wound Infection, Wound Healing Delayed, Wound of Skin, Infections

full page →ctgov ↗
← prev
page 46 of 162
next →
$ABBV246.04+0.89%
$RARE25.91+0.35%
$DFTX46.140.00%
$NVS156.33+1.37%